News

Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

Now Hiring: Lab Manager (San Francisco)

Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

Hexvix® Has Obtained CDE Approval to Carry Out Clinical Real-World Evidence Study

Now Hiring: Clinical Pharmacologist

Now Hiring: Research Associate / Senior Research Associate

Asieris to Increase Presence at ASCO GU 2022

Hexvix® Has Obtained the Approval from the NMPA for Phase Ⅲ Clinical Trial

Now Hiring: Lab & Office Manager (San Francisco)